clinical trial · NCT05815901
A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
JW Pharmaceutical·phase3·completed·n = 612
GoutEpaminurad 6 mgEpaminurad 9 mgFebuxostat 40 mgFebuxostat 80 mgEpaminurad 6 mg placeboEpaminurad 9 mg placeboFebuxostat 40 mg placeboFebuxostat 80 mg placebo
brief summary
A phase 3 clinical trial to compare and evaluate efficacy and safety of epaminurad with febuxostat in gout patients.
started
Mar 21, 2023
primary completion
Mar 26, 2024
completion
Apr 23, 2026
last updated
May 4, 2026
official title
A Multi-center, Randomized, Double-blind, Active-controlled, Therapeutic Confirmatory, Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol